How to Stop Dementia Before it Starts
In a Nutshell
Dementia risk can be cut by over 60% through combined metabolic interventions that address insulin resistance, vascular damage, and chronic inflammation decades before symptoms appear. The most powerful actions are exercise (300+ minutes weekly moderate activity), consistent 7-8 hours of sleep, blood pressure control below 130 systolic, and low-carb diets that allow the brain to use ketones instead of glucose. Additional high-impact steps include treating undiagnosed sleep apnea, checking homocysteine levels with B-vitamin supplementation, and considering ezetimibe over statins for cholesterol management.
These notes were generated by AI and may contain inaccuracies.
Most people hear the word dementia and accept it as something you either get or don't get. Most people, including doctors, treat dementia like a genetic lottery. However, dementia is a metabolic disease, a vascular disease, and an inflammatory disease. Like every metabolic, vascular, and inflammatory disease, it is driven by decades of modifiable risk factors. A 35-year longitudinal study found that combining the right interventions cuts dementia risk by over half, actually over 60%.
The assumption that dementia is inevitable stops people from taking action. Research shows that dementia is not a single disease that descends randomly. It is the downstream result of decades of metabolic, vascular, and inflammatory damage. The same root causes driving cardiovascular disease also drive cognitive decline, including insulin resistance, prediabetes, metabolic disease, chronic inflammation, blood pressure dysregulation, and blood sugar dysregulation. These drivers are behind heart attack, stroke, kidney disease, blindness, and erectile dysfunction. Managing metabolic health protects the brain, and changing the trajectory is possible at any point.
Aging can be sped up depending on lifestyle. Metabolic disease and insulin resistance act like gasoline to a fire, speeding up aging and serving as fuel for dementia. There is no single pill that solves the problem. The 60% risk reduction comes from people who followed a combination of interventions, not one supplement or pill. This represents a comprehensive metabolic and lifestyle approach, validated over 35 years of follow-up in a long-term longitudinal study that has been replicated.
Alzheimer's is the most common type of dementia. In Alzheimer's disease, the brain progressively loses its ability to burn glucose for fuel. This is a full metabolic failure, not a minor slowdown, and it starts years or decades before noticeable symptoms appear. Brain cells are starving for energy even while glucose circulates in the blood because chronic insulin resistance has broken the uptake mechanism.
Dr. Brewer previously worked in Dale Bredesen's ReCODE network. Bredesen wrote the book "The End of Alzheimer's" and discussed 36 holes in the roof, most involving insulin resistance, prediabetes, and metabolic disease. During a training program, Bredesen stated that he believed insulin resistance of the brain was associated with all of Alzheimer's. Research has shown inability to use glucose in the brain even without a body diagnosis of insulin resistance, likely because 90% of people with insulin resistance remain undiagnosed.
A university in North Carolina conducted trials of snorting insulin into the nose to deliver it to the brain for Alzheimer's treatment. While the trial did not work, it underlined that the core mechanism is insulin resistance of the brain. Insulin is part of the memory formation mechanism inside the brain.
The low-carb diet helps bypass the problem completely. When carbohydrates are restricted, the liver produces ketones. Ketones do not require insulin to enter the brain. The brain runs on ketones very well, bypassing the broken glucose pathway and failing insulin receptors. A 2025 study out of the University of Missouri found that a high-fat, low-carb diet may actually prevent amyloid deposition. Amyloid appears to be a byproduct rather than a cause. The low-carb diet prevented amyloid deposition before any symptoms appeared, addressing the brain's energy failure that drives Alzheimer's.
Of every intervention discussed, exercise has the strongest and most consistent evidence across the longest time periods and multiple studies and meta-analyses. No medication in any dementia trial has come anywhere near what physical activity does for the aging brain. Brain exercises like crossword puzzles come way down the list.
A 35-year longitudinal study identified exercise as the single strongest mitigating factor against dementia of all healthy behaviors studied. Midlife exercise (ages 45 to 65) reduces dementia risk by 41%. Late-life exercise (ages 65 to 88) reduces risk by 45%. The benefit does not disappear with age.
The UK Biobank data with over 91,000 participants found that more than 300 minutes a week of moderate to vigorous activity is the threshold associated with substantial risk reduction. This is approximately 45 minutes a day and includes walking, cycling, and resistance training. Condensing activity into a weekend warrior pattern still produced similar protection. For people who cannot manage vigorous activity, 840 minutes per week of light activity like walking was independently protective. A little movement is vastly better than no movement. No drug in any dementia trial has produced these results. The benefit exists at every age.
Sleep is not optional. Every night the brain runs a waste clearance system called the glymphatic system. It flushes beta amyloid and tau proteins out of brain tissue. Sleep is the only time this clearance system fully runs. One bad night of sleep can increase insulin resistance for the next 48 to 72 hours.
People sleeping under 5 hours a night are twice as likely to develop dementia and twice as likely to die compared to people sleeping 6 to 8 hours. Consistently sleeping 6 hours or less at ages 50, 60, and 70 is associated with a 30% increase in dementia risk. Six hours does not protect you. Five hours is dangerous.
There is discussion around statins crossing the blood-brain barrier. Lipophilic statins like atorvastatin cross the blood-brain barrier, while hydrophilic statins like rosuvastatin do not. Some research indicates statins might even prevent dementia. The interventions discussed so far (low-carb diet, exercise, sleep) have not mentioned statins. High-dose statins have been associated with diabetes, which is associated with Alzheimer's and dementia, but high-dose statins are not considered the major cause of diabetes or dementia.
Keeping blood vessels to the brain clean follows the same approach used for every other organ: managing inflammation through diet, exercise, and sleep. These interventions impact arterial health. If plaque has already developed, inflammation can be reduced and plaque stabilized.
Even after plaque has developed over the years, it may not be possible to remove it, but inflammation on the plaque can be reduced and the plaque can be stabilized to reach a much better state.
Sleep apnea is one of the most common undiagnosed sleep problems. The common assumption that sleep apnea only affects people who are severely overweight and snore loudly is not true. A lot of people with sleep apnea have no idea it is happening.
One individual shared their experience of having sleep apnea despite maintaining a BMI between 20 and 22. They noted that sleep apnea does not necessarily wake people up in a way that makes them aware of the condition. Most people with sleep apnea do not know they have it and require input from a sleep partner to identify the problem.
Work with dentists revealed connections between gum disease and pre-diabetes. A narrow dental arch can push the uvula back, contributing to sleep apnea. Learning to sleep on one's side made a significant difference. Mandibular advancement devices were tried but caused bite problems and had to be discontinued.
Sleep is an independent risk factor for cognitive decline. Untreated sleep apnea interrupts oxygen delivery to the brain dozens to hundreds of times per night. This affects both metabolic health and cognitive health. Each night of poor sleep prevents the brain's waste clearance system from fully running, leading to accumulation of damage over decades.
Losing weight is one of the simplest interventions for sleep apnea. One person reported that losing 30 pounds stopped their snoring completely. Weight loss also provided marital benefits. Managing sleep apnea is critical because oxygen deprivation night after night creates a chain reaction where the heart beats faster to compensate, raising blood pressure.
Elevated blood pressure is another factor involved in dementia risk. Midlife hypertension during ages 40s, 50s, and 60s carries a 60% higher risk of later-life dementia. High blood pressure damages small vessels in the brain, causes injury to white matter, drives inflammation in vessel walls, and accumulates amyloid deposition.
The SPRINT MIND study compared standard blood pressure control targeting below 140 against intensive control targeting below 120 systolic. The intensive group had a 19% reduction in mild cognitive impairment. This benefit persisted 7 years after the trial ended. The 2025 American Heart Association and American College of Cardiology guidelines now set a dementia prevention target of systolic blood pressure below 130.
Certain blood pressure medications, specifically potassium-sparing diuretics, may carry additional neuroprotective effects beyond blood pressure reduction. This data is considered soft, but may be worth discussing with a physician, especially for those already on medication and concerned about dementia.
A 2024 analysis of ezetimibe found that people taking it had a sevenfold lower risk of Alzheimer's disease and related dementia. In patients with existing heart disease, the protection was even greater. Ezetimibe blocks cholesterol absorption in the intestine, and the mechanism appears to go beyond cardiovascular benefits through direct interactions between intestinal cholesterol transport and proteins involved in Alzheimer's pathology.
Large meta-analyses involving over a million people show that statin users have roughly 30 to 35% lower risk of Alzheimer's. Not all statins are created equal. Lipophilic statins like atorvastatin and simvastatin cross the blood-brain barrier more readily and may carry more cognitive risk, especially in older patients. Hydrophilic statins like rosuvastatin appear safer for older adults where cognitive side effects are a concern.
Statins are used less than 10% of the time, and not for LDL levels except in specific familial hypercholesterolemia cases. When used, low doses are preferred. The approach differs from both typical medical practice and low-carb content creators who reject all medications. The focus is on plaque and inflammation rather than LDL numbers alone.
Japanese studies tested 2.5 mg and 5 mg of rosuvastatin combined with ezetimibe and found better plaque reversal. Combination of rosuvastatin and ezetimibe could help, but this remains the last step in treatment approach, not the main strategy.
Less than 1% of Alzheimer's cases are purely genetic. At least 40% of cases are related to lifestyle. Hereditary conditions with close relatives having Alzheimer's could increase chances up to 80%, though this may reflect shared lifestyle patterns rather than genetics alone. Someone with family history who adopts healthier lifestyle practices may significantly reduce their risk.
Alcohol is increasingly recognized as harmful rather than beneficial. The previous teaching that moderate alcohol consumption could lower blood pressure or raise HDL is no longer supported. For those with atrial fibrillation, even small amounts of alcohol raise risk with no safe threshold. Zero alcohol consumption appears to be optimal.
Sleep hygiene alone involves multiple interventions. Matthew Walker's book "Why We Sleep" contains practical tips. The combination of magnesium glycinate and L-theanine has positive effects. A sleep ritual with step-by-step routines works better than simply trying to sleep. Changing mindset from "I need to sleep" to "I want to get relaxed" makes falling asleep easier.
Dementia is extremely difficult to reverse, and significant reversals are rare, but they are happening. The Alzheimer's research community agrees that the first person to be cured of Alzheimer's will emerge over the next decade. Even with existing dementia, implementing prevention strategies improves transition and outcomes.
A case was discussed involving a husband diagnosed with Alzheimer's attributed to family history despite normal blood pressure, blood sugar, cholesterol, weight, and MRI results. He did have sleep apnea. He was prescribed a statin and by day three had no memory of what he had done that day. Approximately 2% of people have this reaction to statins. Fasting glucose and A1C miss 50 to 70% of metabolic disease cases.
Repatha and similar PCSK9 inhibitors are popular medications requiring research review for their relationship to dementia prevention.
For patients requiring significant LDL reduction, PCSK9 inhibitors such as evolocumab (Repatha) and alirocumab are injectable biologicals that show at least neutral cognitive outcomes, with some analyses demonstrating better cognitive glide paths compared to statins alone. These medications are not first-line choices for most people but should be considered for high-risk patients or those who cannot tolerate statins. Nexletol (bempedoic acid) is another option, though ezetimibe may be among the most underutilized agents in dementia prevention. Ezetimibe's mechanism appears more direct than initially understood, though it shows limited impact on cardiovascular inflammation and was primarily studied in conjunction with statins.
Homocysteine is an amino acid that builds up naturally in the body. When levels exceed 8 micromoles per liter, methylation problems become a concern, and at 11 micromoles per liter, it begins causing real damage. Elevated homocysteine is independently associated with accelerated brain atrophy and increased dementia risk. A published consensus statement identifies elevated homocysteine as a modifiable risk factor for cognitive decline, dementia, and Alzheimer's disease, describing treatment as easy, inexpensive, and safe. Most standard labs do not include homocysteine testing, requiring patients to specifically request it.
Homocysteine elevation is very common in older adults, with approximately 20% or more of even unusually healthy populations showing levels of 10-11 micromoles per liter. The treatment approach involves B vitamins B6 and B9, specifically a methylated B vitamin complex and trimethylglycine. The body uses methyl groups to clean up oxidative byproducts, similar to how a chemistry lab would neutralize hydrogen and oxygen to form water. B vitamins serve as a storage pool for methyl groups, and over half of the human population has suboptimal methylation due to genetic variations, including MTHFR variations.
Intervention trials demonstrate that lowering homocysteine results in markedly slower brain atrophy and cognitive decline. Vegetarians and vegans face particular risk because B12 comes almost exclusively from animal sources. For individuals with MTHFR variations or other high-risk genetic profiles who have never had homocysteine checked, routine testing should be added to standard lab panels. A simple, inexpensive blood test combined with B vitamin supplementation could address major modifiable risk factors for cognitive decline and Alzheimer's disease.
Observational studies consistently find that people with higher circulating omega-3 levels experience slower cognitive decline, but randomized controlled trials of omega-3 supplementation have not replicated these findings. The evidence for omega-3s in Alzheimer's prevention remains inconclusive. A 2025 large observational analysis found that among older adults, particularly APOE4 carriers, high-dose supplementation was associated with faster cognitive decline. Doses above 1500 mg per day appeared to erase benefits in some subgroups, and omega-3s appear to work only when vitamin B status is adequate.
The practical approach prioritizes obtaining omega-3s from food sources, specifically fatty fish such as salmon, mackerel, herring, and sardines consumed two to three times per week. If supplementing, doses should remain under 1500 mg per day, and homocysteine levels should be addressed first. Elevated homocysteine may prevent proper incorporation of omega-3 fatty acids into brain cell membranes, explaining why supplementation alone may not provide expected benefits when homocysteine is high.
A federally funded trial following 2,802 older adults found that participants completing eight to ten sessions of speed of processing training plus at least one booster session were 25% less likely to receive a dementia diagnosis over the following 20 years. Memory training and reasoning training showed no benefit, only speed of processing training demonstrated protective effects. This represents approximately 10 hours of training providing two decades of protection against Alzheimer's diagnosis.
Observational studies consistently show 30 to 50% lower dementia risk in people with frequent, varied social engagement. Social interaction appears to work through building cognitive reserve, the brain's ability to maintain function despite accumulating damage. For APOE4 gene carriers, high social engagement appears partially able to offset genetic risk. Remaining partially ketogenic or low-ketotic most of the time provides additional benefit for this high-risk group.
Modern research indicates no safe level of alcohol consumption for brain health. Early studies suggesting moderate drinking benefits suffered from a fundamental flaw where the non-drinker category included sick individuals who had stopped drinking due to illness, creating an artificial comparison group that made moderate drinkers appear healthier.
Some individuals on long-term keto diets experience improved lab panels across most markers including lowered insulin, but may see increases in fasting glucose and A1C. Up to 20% of people experience the dawn effect, where cortisol and adrenaline trigger the liver to release stored glycogen into the bloodstream upon waking. This process converts proteins and fats into glycogen for glucose needs, and consuming a small amount of food such as an egg for breakfast typically reduces this fasting glucose elevation.
For A1C, if fasting glucose goes up, the A1C is going to go up. However, A1C can be impacted by a bunch of other things like hemoglobin and red blood cells. The most important marker is that fasting glucose is not going over 126. If fasting glucose chronically exceeds 126, that would be an issue that might need some closer approach.
Inflammation is a major aspect of whether something is working or not, and whether a person is at risk or not. Inflammation testing is typically included in the assessment protocol.
The hosts received a number one fan comment from a viewer. The viewer mentioned wanting to watch a show on sleep featuring Dr. Vega. The hosts acknowledged the request and indicated they might plan something about sleep sooner rather than later if they get enough traction.
The hosts concluded the show, acknowledging it was a long presentation but emphasizing they wanted to give viewers as much information as possible that could be used and applied to avoid dementia. They encouraged viewers to leave any other questions in the comments and mentioned linking a couple of videos in the description.
"I'm loving this show. It's difficult to hold my interest. Thank you."
The hosts thanked Bella Cloud for the feedback and closed the session with music.
Keep Thomas Fordham Brewer MD MPH in your library
Save the videos and channels worth coming back to, and find them again in one place.
